Etanercept for arthritis (juvenile idiopathic) moved to static list

The Department of Health and the Welsh Assembly Government asked the Institute to conduct a review of etanercept for Juvenile Idiopathic Arthritis (JIA) which would additionally include infliximab, and to provide guidance on their use to the NHS in England and Wales.

Infliximab is not currently licensed in the UK for this indication.  After discussion with the manufacturer the Institute has decided to withdraw this drug from the appraisal at this time.

Following consideration of consultation comments received, the existing guidance Arthritis (juvenile idiopathic) - etanercept will become static guidance as it is clear that there is no new research available that would have any material effect on the current guidance. Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect

The list of static technology appraisal guidance will be updated accordingly.